RecruitingNot ApplicableNCT03603730

Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

Modulation of Gastric Sensitivity and Accommodation by Vagal Nerve Stimulation


Sponsor

Massachusetts General Hospital

Enrollment

65 participants

Start Date

Nov 30, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

Explore the effects of auricular transcutaneous vagal nerve stimulation (taVNS) on brain and stomach outcomes in functional dyspepsia and gastroparesis patients.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called taVNS for people with dyspepsia and gastroparesis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEtaVNS

Active or inactive taVNS delivered to the external ear at a moderate, non-painful level.


Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03603730


Related Trials